Vancomycin Dosing in Acute Kidney Injury
In adults with acute kidney injury, vancomycin dosing must be adjusted based on creatinine clearance, with an initial loading dose of at least 15 mg/kg regardless of renal function, followed by maintenance doses calculated as approximately 15 times the glomerular filtration rate in mL/min per day, with close therapeutic drug monitoring to prevent further nephrotoxicity. 1
Initial Loading Dose
All patients with AKI should receive an initial loading dose of at least 15 mg/kg (based on actual body weight), even with mild to moderate renal insufficiency 1. This ensures prompt achievement of therapeutic serum concentrations. Some experts recommend a 25 mg/kg loading dose for serious infections (sepsis, meningitis, pneumonia, endocarditis), though this higher dose may increase early AKI risk 2, 3.
Key point: The loading dose should not be reduced in renal impairment—adequate initial exposure is critical for efficacy, and the loading dose primarily determines volume of distribution, not elimination 1.
Maintenance Dosing Based on Creatinine Clearance
The FDA label provides a clear dosing table for renal impairment 1:
Maintenance Dose = ~15 × CrCl (mL/min) per 24 hours
| Creatinine Clearance (mL/min) | Vancomycin Dose (mg/24h) |
|---|---|
| 100 | 1,545 |
| 90 | 1,390 |
| 80 | 1,235 |
| 70 | 1,080 |
| 60 | 925 |
| 50 | 770 |
| 40 | 620 |
| 30 | 465 |
| 20 | 310 |
| 10 | 155 |
For patients with marked renal impairment, it may be more practical to give maintenance doses of 250-1,000 mg once every several days rather than daily dosing 1. In anuria, a dose of 1,000 mg every 7-10 days has been recommended, with a maintenance requirement of approximately 1.9 mg/kg/24h 1.
Critical Monitoring Considerations
Therapeutic drug monitoring is essential in AKI 4. Patients with unstable or deteriorating renal function require frequent trough monitoring 4. Target trough concentrations are:
- 15-20 mg/L for serious infections (bacteremia, endocarditis, osteomyelitis, meningitis, pneumonia) 4, 2
- 10-15 mg/L for less severe infections 4
Nephrotoxicity Risk in AKI
Common pitfall: Patients with pre-existing AKI are at higher risk for vancomycin-induced nephrotoxicity. Vancomycin-induced nephrotoxicity is defined as 2-3 consecutive increases in serum creatinine (≥0.5 mg/dL or ≥50% from baseline) after several days of therapy, in the absence of alternative explanations 4.
The risk of further renal injury increases with:
- Trough concentrations consistently >20 mg/L 4
- Concurrent nephrotoxic agents 4
- AUC₀₋₂₄ >400 mg·h/L (associated with increased AKI risk despite better efficacy) 3
Do not monitor peak concentrations—this does not reduce nephrotoxicity risk 4.
Infusion Considerations
Each dose should be infused over at least 60 minutes, or at a rate ≤10 mg/min, whichever is longer 1. When individual doses exceed 1 g, extend infusion time to 1.5-2 hours to minimize infusion-related reactions 4.
Estimating Creatinine Clearance in AKI
When only serum creatinine is available, use the Cockcroft-Gault equation 1:
Men: [Weight (kg) × (140 – age)] / [72 × serum creatinine (mg/dL)]
Women: 0.85 × above value
Critical caveat: This calculation is only valid when serum creatinine represents steady-state renal function 1. In AKI with rapidly changing renal function, calculated clearance overestimates actual clearance. In these unstable patients, use the lower end of dosing estimates and monitor troughs more frequently (before the 3rd or 4th dose rather than waiting for steady state) 4.
Practical Algorithm for AKI Patients
- Give loading dose: 15 mg/kg (minimum), consider 25 mg/kg for severe infections
- Calculate CrCl: Use Cockcroft-Gault if stable; if unstable, assume lower function
- Determine maintenance dose: 15 × CrCl (mL/min) per 24 hours
- Adjust dosing interval: For CrCl <50, consider extended intervals (q24-48h or longer)
- Monitor trough before 3rd-4th dose in unstable AKI (rather than standard 4th dose)
- Target trough: 15-20 mg/L for serious infections, 10-15 mg/L otherwise
- Reassess daily: Renal function changes rapidly in AKI—adjust doses accordingly
The 2009 IDSA/ASHP/SIDP guidelines emphasize that standard nomograms were not designed for these higher target concentrations, making individualized pharmacokinetic monitoring particularly important in AKI 4.